



News Release

Takeda Announces Divestment of Multilab to Novamed

Osaka, Japan, April 5, 2018 — Takeda Pharmaceutical Company Limited ([TSE: 4502](#)) today announced it has signed an agreement with Novamed Fabricação de Produtos Farmacêuticos Ltda., (Novamed), to sell/divest all shares, and all its assets in, Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda. to Novamed.

Takeda is committed to continuing to help meet the unmet needs of patients in Brazil and to maintaining its ‘best-in-class’ position in its core therapeutic areas, including Gastroenterology and Oncology. Taking into careful consideration the future development of Multilab's business, Takeda is confident that Novamed, part of the NC Group which owns some of the largest pharmaceutical companies in Brazil, will develop the future business of Multilab by leveraging the synergies of both companies.

1. Overview of Multilab

(1)	Company name	Multilab Indústria e Comércio de Produtos Farmacêuticos Ltda.	
(2)	Headquarters	São Jerônimo, Rio Grande do Sul, Brazil	
(3)	Name of representative	Renata Rodrigues Campos	
(4)	Business description	Research, development, manufacturing and sales of pharmaceutical products	
(5)	Capital	BRL 688 million	
(6)	Date of establishment	1988	
(7)	Major shareholders and percentage of shares held	Takeda Pharma A/S	100%
(8)	Relationships between Takeda and Multilab	Capital relationship	Takeda Pharmaceutical Company Limited holds all the outstanding shares of Takeda Pharma A/S, which holds all of the outstanding shares of Multilab.
		Personnel relationship	Not Applicable
		Transactional relationship	Not Applicable

(9) Operating result and financial conditions for the last three years			
Accounting period	Fiscal year ended March 2015	Fiscal year ended March 2016	Fiscal year ended March 2017
Net assets (million yen)	16,800	10,612	10,276
Total assets (million yen)	21,197	19,175	20,916
Net assets per share (yen)	31.99	20.21	17.58
Sales (million yen)	7,473	5,701	5,390
Operating income (million yen)	-1,831	-2,057	-2,292
Net income (million yen)	-1,917	-3,499	-3,664
Earnings per share (yen)	-3.65	-6.66	-6.42

2. Overview of Novamed

Company name : Novamed Fabricação de Produtos Farmacêuticos Ltda.

Location : Brazil

Relationships between Takeda:

Capital relationship	Not Applicable
Personnel relationship	Not Applicable
Transactional relationship	Not Applicable
Whether Novamed constitutes a related party	Not Applicable

3. Change in Ownership Ratio of Shares through the Divestment

(1) Number of shares held prior to the divestment	688,217,037 shares (Takeda Pharma A/S: 688,217,037 shares) (Number of votes: 688,217,037) (% of total votes: 100%)
(2) Number of shares to be divested	688,217,037 shares (Takeda Pharma A/S: 688,217,037 shares) (Number of votes: 688,217,037)
(3) Number of shares held after the divestment	0 shares (Number of votes: 0) (% of total votes: 0.00%)

The divestment price is undisclosed in accordance with an agreement with Novamed, and was assessed rationally based on discussions between Takeda and Novamed.

4. Schedule of the Divestment

(1) Date of governance meeting resolution	March 20, 2018
(2) Date of conclusion of the agreement	March 22, 2018
(3) Date of transfer of shares	June, 2018 (TBC)

5. Outlook

The impact of the divestment on Takeda's consolidated results for FY2017 is minimal. Takeda's financial forecast for FY2018, including the impact of this divestment, will be announced in May 2018.

Media Contacts:**Media outside Japan**

Vince Docherty

vince.docherty@takeda.com

+65 8332 4233

Japanese Media

Kazumi Kobayashi

kazumi.kobayashi@takeda.com

+81 (0) 3-3278-2095

###